TY - JOUR
T1 - National surveillance of cancer survival in Iran (IRANCANSURV)
T2 - Analysis of data of 15 cancer sites from nine population-based cancer registries
AU - Nemati, Saeed
AU - Saeedi, Elnaz
AU - Lotfi, Fereshte
AU - Nahvijou, Azin
AU - Mohebbi, Elham
AU - Ravankhah, Zahra
AU - Rezaeianzadeh, Abbas
AU - Yaghoobi-Ashrafi, Majid
AU - Pirnejad, Habbiballah
AU - Golpazir, Arash
AU - Dolatkhah, Roya
AU - Alvand, Saba
AU - Ahmadi-Tabatabaei, Seyed Vahid
AU - Cheraghi, Maria
AU - Weiderpass, Elisabete
AU - Bray, Freddie
AU - Coleman, Michel P.
AU - Etemadi, Arash
AU - Khosravi, Ardeshir
AU - Najafi, Farid
AU - Mohagheghi, Mohammad Ali
AU - Roshandel, Gholamreza
AU - Malekzadeh, Reza
AU - Zendehdel, Kazem
N1 - Funding information:
Tehran University of Medical Sciences and
Health Services, Grant/Award Number: IR.
TUMS.VCR.REC.1397.612
Publisher Copyright:
© 2022 UICC.
PY - 2022/12/15
Y1 - 2022/12/15
N2 - Cancer survival is a key indicator for the national cancer control programs. However, survival data in the East Mediterranean region (EMR) are limited. We designed a national cancer survival study based on population-based cancer registries (PBCRs) from nine provinces in Iran. The current study reports 5-year net survival of 15 cancers in Iranian adults (15-99 years) during 2014 to 2015 in nine provinces of Iran. We used data linkages between the cancer registries and the causes of death registry and vital statistics and active follow-up approaches to ascertain the vital status of the patients. Five-year net survival was estimated through the relative survival analysis. We applied the international cancer survival standard weights for age standardization. Five-year survival was highest for prostate cancer (74.9%, 95% CI 73.0, 76.8), followed by breast (74.4%, 95% CI 72.50, 76.3), bladder (70.4%, 95% CI 69.0, 71.8) and cervix (65.2%, 95% CI 60.5, 69.6). Survival was below 25% for cancers of the pancreas, lung, liver, stomach and esophagus. Iranian cancer patients experience a relatively poor prognosis as compared to those in high-income countries. Implementation of early detection programs and improving the quality of care are required to improve the cancer survival among Iranian patients. Further studies are needed to monitor the outcomes of cancer patients in Iran and other EMR countries.
AB - Cancer survival is a key indicator for the national cancer control programs. However, survival data in the East Mediterranean region (EMR) are limited. We designed a national cancer survival study based on population-based cancer registries (PBCRs) from nine provinces in Iran. The current study reports 5-year net survival of 15 cancers in Iranian adults (15-99 years) during 2014 to 2015 in nine provinces of Iran. We used data linkages between the cancer registries and the causes of death registry and vital statistics and active follow-up approaches to ascertain the vital status of the patients. Five-year net survival was estimated through the relative survival analysis. We applied the international cancer survival standard weights for age standardization. Five-year survival was highest for prostate cancer (74.9%, 95% CI 73.0, 76.8), followed by breast (74.4%, 95% CI 72.50, 76.3), bladder (70.4%, 95% CI 69.0, 71.8) and cervix (65.2%, 95% CI 60.5, 69.6). Survival was below 25% for cancers of the pancreas, lung, liver, stomach and esophagus. Iranian cancer patients experience a relatively poor prognosis as compared to those in high-income countries. Implementation of early detection programs and improving the quality of care are required to improve the cancer survival among Iranian patients. Further studies are needed to monitor the outcomes of cancer patients in Iran and other EMR countries.
UR - http://www.scopus.com/inward/record.url?scp=85135451928&partnerID=8YFLogxK
U2 - 10.1002/ijc.34224
DO - 10.1002/ijc.34224
M3 - Article
C2 - 35869869
AN - SCOPUS:85135451928
SN - 0020-7136
VL - 151
SP - 2128
EP - 2135
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 12
ER -
